AMD3100 is a CXCR4 inhibitor that was shown to enhanced multiple therapeutic agents' action on MM cell lines in vitro by disrupting the adhesion to BM stromal cells in a murine myeloma model [104]. Here, CXCR4 is linked to Miyoshi myopathy.